Skip to playerSkip to main content
  • 2 months ago
Shares of Novo Nordisk climbed 4.29% during Friday’s pre-market trading session, after rival Eli Lilly’s Phase 3 ATTAIN-1 trial for obesity drug, orforglipron, trailed the Danish drug giant’s semaglutide on Thursday.

Category

🗞
News
Be the first to comment
Add your comment

Recommended